Taiwan News

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency ...

BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
Nasdaq

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022

TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Becker's Hospital Review

Cryoneurolysis with iovera° for osteoarthritis knee pain: clinical evidence and experience in pre-total knee arthroplasty and non-surgical patients

Effective pain management often relies on administering opioid-based medication, but as opioids have known side effects and can lead to misuse and abuse, alternative approaches that provide ...
manilatimes

Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented ...
Seeking Alpha

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of ...